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Abstract
Objectives—Flat epithelial atypia (FEA) is a relatively new diagnostic term with uncertain
clinical significance for surgical management. Any implied risk of invasive breast cancer
associated with FEA is contingent upon diagnostic reproducibility, yet little is known regarding its
use.
Materials and Methods—Pathologists in the Breast Pathology Study interpreted one of four
60-case test sets, one slide per case, constructed from 240 breast biopsy specimens. An electronic
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data form with standardized diagnostic categories was used; participants were instructed to
indicate all diagnoses present. We assessed participants’ use of FEA as a diagnostic term within:
1) each test set; 2) 72 cases classified by reference as benign without FEA; and 3) six cases
classified by reference as FEA. 115 pathologists participated, providing 6,900 total independent
assessments.
Results—Notation of FEA ranged from 0% to 35% of the cases interpreted, with most
pathologists noting FEA on 4 or more test cases. At least one participant noted FEA in 34 of the
72 benign non-FEA cases. For the 6 reference FEA cases, participant agreement with the case
reference FEA diagnosis ranged from 17% to 52%; diagnoses noted by participating pathologists
for these FEA cases included columnar cell hyperplasia, usual ductal hyperplasia, atypical lobular
hyperplasia, and atypical ductal hyperplasia.
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Conclusions—We observed wide variation in the diagnosis of FEA among U.S. pathologists.
This suggests that perceptions of diagnostic criteria and any implied risk associated with FEA may
also vary. Surgical excision following a core biopsy diagnosis of FEA should be reconsidered and
studied further.
Keywords
breast oncology; atypia; flat epithelial atypia; biopsy; observer variability
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Surgeons rely on the pathologist’s interpretation of a biopsy specimen to guide their
management recommendations for women with abnormalities noted on mammography. This
can be a difficult discussion, especially when carcinoma or atypia is part of the diagnosis.
Many women and physicians are concerned about missing a carcinoma following a core
biopsy diagnosis of atypia. Delay in diagnosis of breast cancer and failure to detect breast
cancer are leading medical malpractice allegations,1 and may further encourage surgical
management for atypical breast biopsy findings including flat epithelial atypia (FEA).
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Up to 10% of core needle breast biopsies may include FEA, a type of proliferative
intraductal epithelium associated with breast microcalcifications detected by radiologic
imaging.2 Each year, 1.6 million breast biopsies are performed on women in the United
States,3,4 suggesting a large number of women will be diagnosed with FEA. The World
Health Organization (WHO) established the defining features of FEA in 2003.5 In the most
recent WHO classification, FEA is defined as “a neoplastic alteration of the terminal-duct
lobular units (TDLUs) characterized by replacement of the native epithelial cells by one to
several layers of a single epithelial cell type showing low-grade (monomorphic) cytological
atypia.”6 This WHO text description is accompanied by photomicrograph examples to assist
distinguishing FEA from other epithelial proliferations with monomorphic cytological
atypia.
Although earlier research posited the theory that pure FEA corresponds to a precursor stage
of ductal carcinoma in situ (DCIS) or invasive carcinoma, most studies have shown that FEA
rarely progresses to carcinoma.7–12 Nevertheless, a diagnosis of FEA includes the word
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“atypia” in its name, potentially causing concern to patients and clinicians. FEA has been
associated with and may coexist with a family of indolent risk-associated proliferative
lesions including atypical lobular hyperplasia (ALH), atypical ductal hyperplasia (ADH),
lobular carcinoma in situ (LCIS), low-grade ductal carcinoma in situ (DCIS), and, less
frequently, low-grade invasive carcinoma.6,13–15 Whether excisional biopsy should be
offered when FEA is the only risk-associated lesion on core biopsy is not currently
standardized.16–19 Uncertainty may encourage excisional biopsy.

Author Manuscript

The surgical outcomes after breast procedures are contingent on the reproducibility and
accuracy of the pathological diagnosis. However, there is little data evaluating FEA as a
diagnostic entity within a broad cross-section of practicing pathologists. In this analysis, we
selected a spectrum of benign breast biopsy cases from the Breast Pathology (B-Path) study.
Among this large cross-section of U.S. pathologists, we examine variability in diagnosis of
FEA. We also identify and describe potential challenges associated with establishing a FEA
diagnosis and the implications for surgical management.

Material and Methods

Author Manuscript

Data for this study originated from the B-Path Study, a large investigation examining
diagnostic under- and over-interpretation of breast biopsy specimens by U.S.
pathologists.20,21 The methods and test sets developed for the B-Path study are described
elsewhere.22,23 In brief, each of four tests sets (A, B, C, and D) of breast biopsy specimens
were created after sampling registries in Vermont and New Hampshire associated with the
Breast Cancer Surveillance Consortium.24 Each test set was composed of 60 cases, one glass
slide per case, randomized with stratification (N=240) to contain comparable pathological
findings. Specimens were from excisional and core biopsies and from female patients ≥40
years of age. All study activities were approved by the Institutional Review Boards at
Dartmouth College, Fred Hutchinson Cancer Research Center, Providence Health &
Services Oregon, University of Vermont, and the University of Washington prior to data
collection.
Reference Diagnosis on Test Cases
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A panel of three experienced breast pathologists established a reference consensus
interpretation for all 240 cases. Blinded to one another’s interpretations, the reference
pathologists used a Breast Pathology Assessment Tool and Hierarchy for Diagnosis
(BPATH-Dx) form to independently review each slide before meeting to establish a
consensus reference diagnosis (Appendix A).25 Pathologists chose 1 or more diagnoses from
14 BPATH-Dx terms, which were grouped into 4 broad diagnostic categories with the
following distribution: 30% benign (including normal breast tissue, non-proliferative
fibrocystic changes, usual ductal hyperplasia [UDH], flat epithelial atypia [FEA], and
atypical lobular hyperplasia [ALH]); 30% atypia (including atypical ductal hyperplasia
[ADH] and intraductal papilloma with ADH); 30% DCIS; and 10% invasive carcinoma.
ALH was included in the benign category exclusively for analytic reasons because lobular
lesions were not a major focus of the main B-Path study.
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Following reference consensus interpretation, there were six reference FEA cases that had
FEA only or a combination of FEA and other lesions categorized as benign according to a
consensus or majority of reference panel pathologists (Appendix B). FEA was the highest
category lesion in all six cases. Three reference FEA cases (numbers 1, 2, and 5) were not
reviewed during the consensus meetings because all three reference panel pathologists
independently agreed on a benign proliferative diagnosis. In all three cases, two out of three
reference pathologists (a majority) noted the presence of FEA on their independent
interpretations. The remaining three reference FEA cases (numbers 3, 4, and 6) did not have
definitive independent diagnostic agreement and were reviewed at consensus meetings,
during which all three reference pathologists agreed on the presence of FEA and no higherranking diagnoses. A qualitative analysis of the consensus process for B-Path indicated that
the most common reason underlying the need for consensus was differing opinions
regarding whether a particular lesion, such as FEA, met diagnostic criteria.25
There were 72 benign non-FEA reference cases according to the consensus or majority of
reference panel pathologists. The non-FEA cases comprised a spectrum of benign findings;
individual slides may have included normal breast tissue, columnar cell change and
hyperplasia (CCH), UDH, or ALH. Cases where only one reference pathologist indicated the
presence of FEA were not excluded.
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We considered the presence of other diagnoses in case selection because excision of
proliferative lesions identified on core biopsy is often based on published associations with
more severe disease on excisional biopsy (i.e., upstaging). For example, surgical excision is
not routinely recommended for UDH, whereas many centers excise FEA if found on core
needle biopsy.5,26,27 Excision for ALH on core biopsy is controversial; studies have shown
that it may pose few risks, or its risk may depend on the extent of its presence.28–34 Thus,
we included cases of FEA with UDH or ALH. We excluded cases of FEA with coexisting
higher category lesions, including cases where the reference panel diagnosis noted ADH,
intraductal papilloma with atypia (IPA), DCIS, or invasive cancer. It is not always standard
practice for a pathologist to note all diagnostic lesions present on a slide, especially for
lesions with lower risk relative to the primary diagnosis.
For the global assessment of the proportion of cases in each test set where the study
participants noted FEA on the diagnostic form, we used all test set cases except those with
invasive carcinoma. Random stratification of the 240 test cases into 4 test sets resulted in the
following distribution of reference FEA cases: 3 in test set A, 2 in test set B, and 1 in test set
C. FEA was not a random stratification variable for creating the test sets.

Author Manuscript

Participating Pathologist Recruitment and Characteristics
Pathologists with at least one year of experience interpreting breast specimens and who
planned to continue practicing diagnostic breast pathology for at least one more year were
recruited from eight states (AK, ME, MN, NH, NM, OR, VT, and WA). Pathology residents
and fellows were excluded. After providing informed consent, all participants completed a
web-based survey of demographic information and clinical practice characteristics.
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Participating pathologists were randomly assigned with stratification on clinical expertise to
independently interpret one of four test sets. Participants received one Hematoxylin and
Eosin-stained (H&E) glass slide per case. All participants assigned to the same test set
received the same slides. Pathologists were asked to assess cases and note all of the lesions
present; there were no study-specific time constraints. Participants completed the same
BPATH-Dx form for each case online that had been developed and used by the reference
pathologists. We then determined the proportion of cases where FEA was identified out of
60 cases (a complete test-set) by each participant, the proportion of cases where FEA was
identified among the subset of reference non-FEA benign cases, and, finally, the
participants’ proportional agreement with the six reference FEA cases.

Author Manuscript

Results
Participating Pathologists’ Characteristics
Of 691 pathologists invited to join the B-Path study, 126 were randomly assigned to interpret
the glass slide test sets. In total, 91% (115/126) independently interpreted all 60 cases in
their assigned test set. Most (75.7%) did not have an academic affiliation, 51.3% had
completed a fellowship in either surgical pathology or breast pathology, 21.7% reported
being considered experts in breast pathology by their colleagues, and 59.1% worked in
laboratory practices with fewer than ten pathologists.
Global use of FEA Diagnostic Term by Pathologists for the 60-Case Test Sets

Author Manuscript

Figure 1 shows the proportion of all test cases where participants and reference pathologists
noted FEA during their initial independent interpretations. While the majority of
pathologists noted FEA on 4 or more of the 60 test cases they interpreted, 9 (8%)
participating pathologists identified FEA in ≥20% of the test cases, and 19 (17%)
pathologists identified FEA in ≥15% of the cases. The reference pathologists also
independently differed in the frequency with which they used the FEA diagnostic category
(<5% to 20% of test cases).
Participating Pathologists’ Assessments of Reference non-FEA Benign Cases

Author Manuscript

One or more participants noted the presence of FEA on 34 of the 72 reference non-FEA
benign cases (Table 1). Four of the 34 cases (11.8%) were independently noted to have FEA
by 1 reference pathologist, even though they did not qualify as reference FEA cases based
on consensus or the majority of reference pathologists. Six of the 34 cases were noted as
having FEA by 20% or more of the participating pathologists. Common reference diagnoses
for these 34 cases included CCH, UDH, and ALH.
Participating Pathologists’ Assessments on the 6 Reference FEA Cases
The study pathologists who interpreted the 6 reference FEA cases provided a total of 175
individual interpretations (29 to 30 participants interpreted each case). Many participants
listed multiple lesion types in their interpretations (Appendix B). Pathologists demonstrated
the highest rate of agreement with the reference FEA diagnosis for case 1 (52%) and the
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lowest rate of agreement for case 6 (17%). Figure 2 shows common diagnoses by
participants including CCH, UDH, ADH, and alternative benign lesions.

Discussion
We observed extensive and concerning variability in use of the FEA diagnostic term by
practicing U.S. pathologists. Some pathologists identified FEA in more than 20% of the
breast biopsy slides they interpreted, while others refrained from using the FEA term
entirely. This variability likely represents a combination of differing thresholds for including
a proliferative lesion in the FEA category, varied understanding or application of diagnostic
criteria, and the challenge associated with assigning a categorical diagnosis to a continuum
of histopathological features.

Author Manuscript

The implications for surgical management of CCH and ADH are generally different than
those suggested for FEA. A diagnosis of CCH does not warrant further treatment whether
diagnosed on a core or excisional biopsy, whereas women with ADH are considered at
increased risk of developing breast cancer and typically undergo excisional biopsy following
a core biopsy diagnosis to exclude low-grade DCIS. When the final diagnosis is ADH, some
women consider heightened surveillance and risk reduction using hormonal or surgical
treatments.35–37 Both ADH and FEA may have adjacent coexisting disease such as lowgrade DCIS and low- grade invasive carcinomas, including tubular carcinomas. For this
reason, some argue that FEA diagnosed on core biopsy should be followed by excisional
biopsy to exclude an adjacent low-grade carcinoma. The counter argument is that the
associated coexisting disease is relatively indolent and could be managed with
surveillance.8–10,16,17,19 In addition, the intrinsic biologic risk for future breast cancer is
considerably lower for FEA than for ADH.38
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The surgical management of FEA is complicated by the potential magnitude of its
prevalence in clinical practice. Previous research suggests that up to 10% of all core needle
breast biopsies may have FEA noted by the interpreting pathologist.2 Our study corroborates
these observations. Although studies have evaluated the incidence of breast cancer in women
with FEA,39,40 their applicability relies on the reproducibility of FEA as a diagnostic entity.
Other studies have found only moderate agreement (Kappa=0.47) for diagnoses of FEA.41
Pathologists with a special interest in breast pathology are better at distinguishing FEA from
other lesions when tested immediately after a brief educational intervention.42,43 Thus, it is
possible that the diagnosis of FEA can be improved through education. Figure 3 and Figure
4 describe some of the educational issues associated with a diagnosis of FEA.
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Our study evaluated interpretive variability among a large number of practicing U.S.
pathologists within a spectrum of cases that were also evaluated by a reference panel. The
reference panel members also demonstrated substantial variability in their interpretation of
FEA; however, overall prevalence of FEA decreased following the consensus review process
that included a discussion of diagnostic criteria. This observation suggests that educational
interventions may refine understanding of the diagnostic criteria and potentially reduce the
diagnostic prevalence. Open discussion and communication between radiologists,
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pathologists, and breast surgeons is perhaps more important than improving pathologist
reproducibility. Our mutual goal is to segregate lesions associated with future risk of
developing cancer from lesions associated with current risk for associated aggressive lesions
that require early intervention and treatment. FEA and its associated family of indolent
lesions, including ADH, ALH, low-grade DCIS, and small well-differentiated or tubular
carcinomas are increasingly recognized as lesions that do not pose an immediate threat for
women participating in breast screening.
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Translating test set evaluation to clinical performance has limitations, and the issues
requiring special consideration are described elsewhere.20,23,25 We also noted a difference
among participants’ use of the BPATH-Dx form, with most checking multiple boxes, and
some selecting a single, highest order diagnosis despite being instructed to check all
applicable diagnostic boxes. We do not know how the order of slides within test sets (which
was different for each participant), the oversampling of cases with atypia and DCIS, and the
use of both excisional and core needle biopsies may have affected diagnoses. Participants
tended to diagnose FEA more often on core biopsies, compared with excisional biopsies;
however, the sample size was too small to draw any conclusions from this trend.
In summary, our findings show a high degree of variability in the use of FEA as a diagnostic
entity among practicing U.S. pathologists and suggest that differences between FEA, CCH,
UDH, and ALH should be discussed in greater detail during clinical case review. Our results
emphasize the challenges that breast surgeons face when relying on pathologists’ reports and
stress the need for cross-discipline understanding of diagnostic variability in potentially
precancerous lesions.
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Appendix A. BPATH-Dx Histology Form for Data Collection on Each Case
Used by Participating Pathologists. Originally published in K Allison et al
(2014).19
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Appendix B. Participating pathologists’ interpretations of reference FEA
Author Manuscript

cases*

Case Number
1

Reference Panel diagnosis**
(FEA)

Core or excisional

N
(Practicing
Pathologists
Interpreting
a case)

Needle Core

29
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Number of
Pathologists
who Agree
with the
Reference
Diagnosis
of FEA
15 (52%)

If pathologist does not diag
Alternative

RS
7 (24%)

1 (3%)

SA
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Case Number

Reference Panel diagnosis**

Core or excisional

N
(Practicing
Pathologists
Interpreting
a case)

Number of
Pathologists
who Agree
with the
Reference
Diagnosis
of FEA

If pathologist does not diag
Alternative

RS

2

(FEA)

Needle Core

29

11 (38%)

20 (69%)

4 (14%)

3

FEA, CCH

Needle Core

29

10 (34%)

17 (59%)

1 (3%)

4

FEA, ALH

Excisional

29

8 (28%)

13 (45%)

5

(UDH, FEA)

Excisional

29

7 (24%)

15 (52%)

10(34%)

6

FEA, UDH, CCH

Excisional

30

5 (17%)

11 (37%)

17(57%)

Author Manuscript

Diagnostic Category Appreciations: FEA: Flat Epithelial Atypia, CCH: Columnar Cell Hyperplasia, UDH: Usual Ductal
Hyperplasia, RS: Radial Scar/Complex Sclerosing lesion, SA: Sclerosing Adenosis, IPW: Intraductal Hyperplasia Without
Atypia, FA: Fibroadenoma, ALH: Atypical Lobular Hyperplasia, NP: Non-Proliferative, ADH: Atypical Ductal
Hyperplasia, DCIS: Ductal Carcinoma In Situ

*
Percentages add up to >100% because participants could mark combinations of lesion types for a single case
**
Parentheses indicate that the case did not go to consensus. When a case did not got to consensus, the reference diagnosis
was determined based on which lesions were identified by two or more reference pathologists.
***
See Figure 2 for a bar graph of data specified in this appendix B.
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2 (7%

1 (3%

5 (17%
8 (27%)

3 (10%
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Highlights
•

We observed wide variation in the diagnosis of FEA among U.S. pathologists.

•

Perceptions of diagnostic criteria and any implied risk for FEA may also vary.

•

FEA, CCH, UDH, and ALH should be compared in greater detail during case
review.

•

Surgical excision following core biopsy diagnosis of FEA may not be
necessary.

•

Educational interventions may refine understanding, reduce diagnostic
variation.
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Fig. 1.

Percentage of B-Path test set cases interpreted as having FEA present on the glass slide, with
results shown for each participating pathologist and the three reference pathologists,
organized according to test seta
a. Each test set was composed of 60 cases. Cases may have been given other higher order
interpretations along with the diagnosis of FEA. Cases with higher order interpretations and
cases identified as FEA by only a single reference panel pathologist were not used as
reference FEA cases.
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Fig. 2.

Frequency of diagnostic terms used by participating pathologists for reference FEA casesa
a. All six reference FEA cases had FEA only, or a combination of FEA and other lesions
categorized as benign without atypia according to the reference panel. Percentages add up to
>100% because participants could mark combinations of lesion types for a single case. See
Appendix B for a table showing the reference diagnosis for each case and the number of
participants who interpreted each lesion.
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Fig. 3. Images and discussion points for three cases classified as FEA by reference pathologists

Author Manuscript

Fig. 3a) Case #1 Focus of FEA with intraluminal secretions. This lesion has round to ovoid
monomorphic nuclei with some cellular stratification. In areas, the cells are oriented
perpendicularly to the basement membrane reminiscent of columnar cell change, but in other
areas, the cells lose this arrangement. Note the lack of slender, bland nuclei typical of
columnar cell change and the presence of the more rounded nuclear contour of FEA. 2 of the
3 reference pathologists diagnosed this case as FEA. 52% of participating pathologists
(N=29) interpreted this as FEA. Hematoxylin and eosin, 400X and 40X
Fig. 3b) Case #3 Focus of FEA in an enlarged TDLU. From low magnification (inset), note
the dilated, hyperchromatic ducts that raise concern for FEA at scanning magnification. At
higher magnification, the ducts are filled with rounded monomorphic cells that are not
regularly oriented perpendicular to the basement membrane. There is cellular stratification
and, although there are no prominent nucleoli or obvious chromatin margination, the cells
resemble those seen in low grade ductal carcinoma in-situ. This lesion was interpreted as
FEA by 34% of participating pathologists (N=29)
Fig. 3c) Case #5 Focus of FEA with prominent apical cytoplasmic snouting. From scanning
magnification (inset), there are dilated ducts with round contours and hyperchromasia
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suggestive of FEA. At higher magnification, although there is no cellular stratification, the
nuclei are round with a high nuclear to cytoplasmic ratio and prominent chromatin
margination characteristic of FEA. 2 of the 3 reference pathologists diagnosed this case as
FEA. This lesion was interpreted as FEA by 24% of participating pathologists (N=29)
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Fig. 4. Images and discussion points for three cases classified as benign or ALH without FEA by
reference pathologists. These cases were frequently interpreted as FEA by participating
pathologists
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Fig. 4a) Case #7 Focus of columnar cell change and columnar cell hyperplasia in enlarged
TLDUs with intraluminal calcifications. Although the nuclei of the cells lining the TLDUs
in this lesion show mild pleomorphism, the cells are arranged perpendicularly to the
basement membrane and do not have the round to ovoid monomorphic nuclei typical of
FEA. The nuclear pleomorphism likely results from reaction to the intraluminal
calcification. This lesion was interpreted as FEA by 67% of participating pathologists
(N=27). Hematoxylin and eosin, 400X and 40X
Fig. 4b) Case #8 Focus of non-atypical proliferative change with enlarged terminal ductal
lobular units (TLDUs) with irregular contours and usual ductal hyperplasia. Although from
low power (see inset), the lesion is hyperchromatic, raising the possibility of FEA, at higher
power, the cells are cytologically benign and are arranged in a haphazard pattern with poorly
defined borders characteristic of usual ductal hyperplasia. Note the absence of low grade
monomorphic round to ovoid nuclei typical of FEA. This lesion was interpreted as FEA by
37% of participating pathologists (N=30)
Fig. 4c) Case #10 Focus of columnar cell change in enlarged TDLUs. From low
magnification (inset) the lesion has dilated ducts with round contours and mild
hyperchromasia that is suggestive of FEA. However, at higher magnification, there is a
single layer of non-atypical columnar to cuboidal cells with cytoplasmic snouts, intraluminal
secretions and calcifications. The nuclei are arranged perpendicular to the basement
membrane with evenly dispersed chromatin and no obvious nucleoli. These are features
Breast. Author manuscript; available in PMC 2018 August 01.
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more consistent with columnar cell change rather than FEA. This lesion was interpreted as
FEA by 23% of participating pathologists (N=30)
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Breast biopsy cases defined as benign with no FEA by the reference consensus panel, yet identified as FEA by
one or more participating pathologists.

Case Number

FEA was independently
identified by at least one
reference panel member

Reference panel diagnosisa

Number of Participants who identified FEA/
Number of Participants who independently
interpreted the case (%)

Author Manuscript
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7

Yes

(CCH)

18/27

(66.7%)

8

No

(UDH, CCH)

11/30

(36.7%)

9

Yes

ALH, UDH, CCH

8/30

(26.7%)

10

Yes

ALH, UDH, CCH

7/30

(23.3%)

11

Yes

UDH

6/29

(20.7%)

12

No

Fibroadenoma

6/30

(20.0%)

13

No

(UDH, CCH)

5/27

(18.5%)

14

No

UDH, CCH

4/27

(14.8%)

15

No

(NPR)

4/29

(13.8%)

16

No

(CCH)

4/30

(13.3%)

17

No

CCH

3/27

(11.1%)

18

No

UDH

3/29

(10.3%)

19

No

UDH

3/29

(10.3%)

20

No

LCIS, IPW, UDH,CCH

3/30

(10.0%)

21

No

(UDH, CCH, Fib)

3/30

(10.0%)

22

No

(UDH)

2/27

(7.4%)

23

No

(UDH)

2/29

(6.9%)

24

No

ALH, UDH

2/29

(6.8%)

25

No

(UDH, CCH)

2/29

(6.9%)

26

No

(CCH, SCL)

2/29

(6.9%)

27

No

RSL

2/29

(6.9%)

28

No

ALH, UDH, RSL

2/30

(6.7%)

29

No

NPR

2/30

(6.7%)

30

No

UDH

2/30

(6.7%)

31

No

(CCH, RSL, ALH)

1/27

(3.7%)

32

No

(UDH)

1/27

(3.7%)

33

No

(UDH, CCH)

1/27

(3.7%)

34

No

NPR

1/27

(3.7%)

35

No

Fibroadenoma

1/27

(3.7%)

36

No

UDH

1/29

(3.4%)

37

No

(NPR)

1/29

(3.4%)

38

No

(NPR)

1/29

(3.4%)

39

No

NPR

1/29

(3.4%)

40

No

(NPR)

1/30

(3.3%)

Breast. Author manuscript; available in PMC 2018 August 01.

Samples et al.

Page 20

a

Parentheses indicate that the case did not go to consensus. When a case did not go to consensus, the reference diagnosis was determined based on
which lesions were identified by two or more reference pathologists.
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FEA = flat epithelial atypia; CCH = columnar cell change or hyperplasia; UDH = usual ductal hyperplasia; ALH = atypical lobular hyperplasia;
NPR = non-proliferative changes only; LCIS = lobular carcinoma in situ; IPW = intraductal papilloma without atypia; Fib = fibroadenoma; RSL =
radial scar/complex sclerosing lesion.
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